Abstracts tagged "Biologic drugs"

Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Gerd R. Burmester¹, Owen Hagino², Qunming Dong³, Marina Stanislav⁴, Antonio Gomez-Centeno⁵, Carlo Selmi⁶, Tom W.J. Huizinga⁷, Erin Mangan⁸, Cem Gabay⁹ and Mark C. Genovese¹⁰, ¹Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Sanofi Genzyme, Bridgewater, NJ, ³Sanofi, Bridgewater, NJ, ⁴Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, ⁵Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁶Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁹University Hospitals of Geneva, Geneva, Switzerland, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
Abstract Number: 2539 • 2018 ACR/ARHP Annual Meeting
SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
Diederik De Cock¹, Lianne Kearsley-Fleet², Rebecca Davies², Kath Watson² and Kimme L. Hyrich^1,3, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In the United Kingdom (UK) since 2016, etanercept biosimilars (SB4) are since 2016 a first-line treatment option for the management of severe rheumatoid arthritis…
Abstract Number: 1533 • 2018 ACR/ARHP Annual Meeting
Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
Josephine Mauskopf¹, Mahdi Gharaibeh², David Wamble¹, David H. Collier², Bradley S. Stolshek² and Eric L. Matteson³, ¹RTI Health Solutions, Research Triangle Park, NC, ²Amgen Inc., Thousand Oaks, CA, ³Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes joint pain and swelling, bone erosions, and deformity. This debilitating disease can severely…
Abstract Number: 2559 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Ana-Maria Orbai¹, Amanda M. Gellett², Lisa Kerr² and Arnaud Constantin³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Hopital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets IL-17A, was superior to placebo (PBO) at Week (Wk) 24 for treating PsA signs and…
Abstract Number: 1534 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
Rishi J. Desai¹, Sara Dejene², Yinzhu Jin², Jun Liu³ and Seoyoung C. Kim², ¹Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) often develop diabetes mellitus (DM), potentially due to aggravated systemic inflammation. Reducing inflammation with disease-modifying antirheumatic drugs (DMARD) may…
Abstract Number: 2596 • 2018 ACR/ARHP Annual Meeting
Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Elsa Vieira-Sousa^1,2, Mónica Eusébio³, Pedro Ávila-Ribeiro^1,2, Nikita Khmelinskii^1,2, Ana Rita Machado^1,2, Teresa Martins-Rocha^4,5, Miguel Bernardes^4,5, Daniela Santos Faria⁶, Joana Leite Silva⁶, Helena Santos⁷, Cláudia Miguel⁷, Pedro Carvalho^8,9, Tiago Costa¹⁰, Lídia Teixeira¹¹, Tiago Meirinhos¹², Patrícia Nero¹³ and Maria José Santos^11,14, ¹Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ²Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ³Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ⁴Serviços de Reumatologia do Centro Hospitalar São João do Porto, Porto, Portugal, Porto, Portugal, ⁵Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal, Porto, Portugal, ⁶Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁷Instituto Português de Reumatologia Lisboa, Portugal, Lisboa, Portugal, ⁸Serviço de Reumatologia, Hospitais Universitários de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁹Serviço de Reumatologia, Centro Hospitalar e Universitário do Algarve, Faro, Portugal, Faro, Portugal, ¹⁰Serviço de Reumatologia do Hospital Egas Moniz, Lisboa, Portugal, Lisboa, Portugal, ¹¹Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹²Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal, ¹³Hospital CUF Descobertas, Lisboa, Portugal, Lisboa, Portugal, ¹⁴Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, Lisboa, Portugal
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) lead to a dramatic improvement in the management of psoriatic arthritis (PsA). Nevertheless, a significant proportion of patients…
Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Josef S. Smolen¹, David Shrom², Chen-Yen Lin², Julie Birt², Georg Schett³ and Alice B Gottlieb⁴, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, ⁴Department of Dermatology, New York Medical College, New York, NY
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…
Abstract Number: 2610 • 2018 ACR/ARHP Annual Meeting
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Johanna Gehin¹, Silje Watterdal Syversen², Guro Løvik Goll², David J Warren¹, Joseph Sexton³, Eldri Kvein Strand⁴, Tore Kvien^3,5,6, Elisabeth Lie^2,6 and Nils Bolstad⁷, ¹Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Lillehammer Revmatismesykehus, Lillehammer, Norway, ⁵NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁶On behalf of the NOR-DMARD registry, Oslo, Norway, ⁷Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway
Background/Purpose: Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors.An association between certolizumab pegol (CP) serum levels and response has previously been…
Abstract Number: 1723 • 2018 ACR/ARHP Annual Meeting
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
Daniela Rossi¹, Irene Cecchi², Massimo Radin³, Elena Rubini⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose:Systemic sclerosis (SSc) is a connective tissue autoimmune disease with systemic involvement and a serious medical condition with a high rate of mortality, especially due…
Abstract Number: 2618 • 2018 ACR/ARHP Annual Meeting
Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
Jean-Guillaume Letarouilly¹, Jeremie Sellam², Pascal Richette³, Philippe Dieude⁴, Pascal Claudepierre⁵, Tristan Pascart⁶, Eric Houvenagel⁶, Marie-Hélène Guyot⁷, Nicolas Segaud⁸, Pascal Coquerelle⁹, Frederic Maury¹⁰, Laurent Marguerie¹¹, Xavier Deprez¹², Jean-Hugues Salmon¹³, Guy Baudens¹², Elisabeth Gervais¹⁴, Maeva Kyheng¹⁵, Julien Paccou¹ and René-Marc Flipo¹, ¹Rheumatology, Lille University Hospital, Lille, France, ²AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ³Rheumatology, Université Paris Diderot, Paris, France, ⁴Université Paris-Diderot, Paris, France, ⁵Hôpital Henri Mondor, Créteil, France, ⁶Rheumatology, Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁷Internal medicine, Hospital of Roubaix, Roubaix, France, ⁸Internal medicine, Hospital of Armentieres, Armentières, France, ⁹rheumatology, Hospital of Bethune, Bethune, France, ¹⁰Rheumatology, Private Practice, Beuvry, France, ¹¹Rheumatology, Institut Calot, Berck, France, ¹²Rheumatology, CHR Valenciennes, Valenciennes, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Rhumatologie, University Hospital, Poitiers, France, ¹⁵Lille University Hospital, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000, Lille, France
Background/Purpose: Ustekinumab and secukinumab are two new Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) in severe psoriatic arthritis (PsA), targeting respectively IL12-23 and IL 17. Data in…
Abstract Number: 227 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
Kathrine Lederballe Grøn¹, Elizabeth V. Arkema², Bente Glintborg¹, Frank Mehnert³, Mikkel Østergaard⁴, Lene Dreyer⁵, Mette Nørgaard³, Niels Steen Krogh⁶, Johan Askling⁷ and Merete Lund Hetland⁸, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Aarhus University Hospital, Clinical Epidemiological Department, Aarhus, Denmark, ⁴The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁵Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ⁶ZiteLab ApS, Copenhagen, Denmark, ⁷Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Background/Purpose: Safety concerns have been raised regarding the risk of serious infections (SI) with the different available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Little is known…
Abstract Number: 1829 • 2018 ACR/ARHP Annual Meeting
Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis
Julia Manasson¹, Lu Yang², Gary E. Solomon¹, Soumya M. Reddy¹, Parvathy V. Girija¹, Andrea L. Neimann³, Leopoldo N. Segal⁴, Carles Ubeda⁵, Jose C. Clemente⁶ and Jose U. Scher⁷, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Department of Dermatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Pulmonary and Critical Care, New York University School of Medicine, New York City, NY, ⁵Institute for Research in Public Health (FISABIO), Valencia, Spain, ⁶Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: The microbiome serves a number of important functions, including modulation of the immune system and protection from pathogenic microorganisms1. Many autoimmune diseases have been…
Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud^1,2, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…
Abstract Number: 575 • 2018 ACR/ARHP Annual Meeting
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Elliot Hepworth², Reza Mirza², Angela Cesta³, Maggie Larche⁴ and Claire Bombardier^1,5,6, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ³Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁴Medicine, McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However,…
Abstract Number: 1933 • 2018 ACR/ARHP Annual Meeting
Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation
Stefano Alivernini¹, Barbara Tolusso¹, Aziza Elmesmari², Laura Bui³, Giusy Peluso¹, Maria Rita Gigante¹, Samuel Finlay^2,4, Luca Petricca¹, Clara Di Mario¹, Simone Perniola^1,5, Anna Laura Fedele¹, Francesco Federico³, Iain B. McInnes^2,4, Gianfranco Ferraccioli¹, Mariola Kurowska-Stolarska^2,6 and Elisa Gremese¹, ¹Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Catholic University of the Sacred Heart, Rome, Italy, ²Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Catholic University of the Sacred Heart, Rome, Italy, ⁴Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), Glasgow, United Kingdom, ⁵Department of Verona - University of Verona (ITALY), Verona, Italy, ⁶Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), Rome, Italy
Background/Purpose: Flares of immune-mediated inflammatory diseases, as Rheumatoid Arthritis (RA) occur unpredictably representing a major burden for patients and clinicians. We aimed to dissect the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].